Curative effect of long-term low-dose azithromycin in treatment of bronchiectasis
LIU Xiaohua1, PIAO Yuxin1, CHAI Wenqiang1, FAN Chaoyu1, LI Dawen2
1. The First Department of Internal Medicine,2. the First Department of Surgery, Inner Mongolian Autonomous Regional Corps Hospital of Chinese People's Armed Police Force, Huhhot 010040, China
Abstract：Objective To analyze the curative effect of long-term low-dose azithromycin in the treatment of bronchiectasis. Methods A total of 98 patients with bronchiectasis admitted to Inner Mongolian Autonomous Regional Corps Hospital of Chinese People's Armed Police Force from June 2021 to March 2024 were divided into a control group and an observation group, with 49 cases in each group according to random number table method, The control group received conventional symptomatic treatment, while the observation group received long-term low-dose azithromycin treatment on the basis of the control group. After 6 months, the clinical efficacy, dyspnea, sputum characteristics and airway inflammation were compared between the two groups. Results After treatment, the total effective rate of the observation group was 91.84%, which was higher than that of the control group (75.51%) (P<0.05). The Saint George's Respiratory Questionnaire (SGRQ) score of the observation group was (44.33±13.69), which was lower than that of the control group (58.88±14.29). The modified Medical Research Council Dyspnea Scale (mMRC) score was (2.08±0.40), which was lower than that of the control group (2.71±0.46). The differences were statistically significant (P<0.05). The 24-hour sputum volume of the observation group was lower than that of the control group, and the sputum density and purulent mucus scores were lower than those of the control group. The expressions of sputum interleukin-6 (IL-6), 65 subunit protein (p65) and high-sensitivity C-reactive protein (hs-CRP) were lower than those of the control group. The differences were statistically significant (P<0.05). Conclusions The clinical value of long-term low-dose azithromycin treatment for bronchiectasis is significant, which is helpful to improve the curative effect of patients, relieve the degree of dyspnea, and promote the improvement of sputum characteristics and airway inflammation.
Martinez-Garcia M A, Posadas T, Sotgiu G, et al. Role of inhaled corticosteroids in reducing exacerbations in bronchiectasis patients with blood eosinophilia pooled post-hoc analysis of 2 randomized clinical trials[J].Resp Med,2020,172(9):106127-106127.
RhaziK E,Nejjari C,Benjelloun M C,et al.Validation of the St.George's respiratory questionnaire in patients with COPD or asthma in Morocco[J].Int J Tuberc Lung D,2006,10(11):1273-1278.
[8]
Bestall JC, Paul EA, Garrod R, et al. Usefulness of the medical research council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease[J].Thorax,1999,54(7):581-586.
Bacharier L B.Azithromycin during wheezing illnesses among preschool children:does the airway microbiota provide insights into mechanism[J].Am J Respir Crit Care Med,2021,204(2):115-116.
2025, Vol. 36 
